BioCentury
ARTICLE | Clinical News

Vanda gains on Phase III sleep disorder data

December 19, 2012 2:15 AM UTC

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) jumped $0.61 (19%) to $3.83 on Tuesday after oral tasimelteon met the co-primary endpoints in the 84-patient Phase III SET trial to treat non-24-hour sleep wake disorder. Top-line data from the Phase III RESET trial are expected next quarter, with an NDA submission for tasimelteon slated for mid-2013. The product has Orphan Drug designation in the U.S. and EU to treat non-24-hour sleep wake disorder in blind patients without light perception. ...